Hong Kong Baptist University School of Chinese Medicine

HKBU develops Chinese medicine new formula for treating Alzheimer's disease

Retrieved on: 
Wednesday, February 3, 2021
Alternative medicine, Pharmacy in China, Pseudoscience, Traditional Chinese medicine, Traditional medicine, Hong Kong Baptist University, Articles, Health, Education, Hong Kong Baptist University School of Chinese Medicine

HONG KONG, Feb. 3, 2021 /PRNewswire/ -- Researchers from the School of Chinese Medicine (SCM) at Hong Kong Baptist University (HKBU) have developed a Chinese medicine formula named NeuroDefend that offers a potentialnovel treatment for Alzheimer's disease (AD).

Key Points: 
  • HONG KONG, Feb. 3, 2021 /PRNewswire/ -- Researchers from the School of Chinese Medicine (SCM) at Hong Kong Baptist University (HKBU) have developed a Chinese medicine formula named NeuroDefend that offers a potentialnovel treatment for Alzheimer's disease (AD).
  • NeuroDefend was developed by a research team led by Professor Li Min, Professor of the Teaching and Research Division and Associate Dean of the School of Chinese Medicine at HKBU.
  • Three of them were found to be effective in treating Alzheimer's disease in a cell disease model.
  • "Traditional Chinese medicine adopts a broad pharmacological approach to treating neurodegenerative diseases by deploying a combination of herbal medicines with different treatment effects.

HKBU develops Chinese medicine new formula for treating Alzheimer's disease

Retrieved on: 
Wednesday, February 3, 2021
Alternative medicine, Pharmacy in China, Pseudoscience, Traditional Chinese medicine, Traditional medicine, Hong Kong Baptist University, Articles, Health, Education, Hong Kong Baptist University School of Chinese Medicine

HONG KONG, Feb. 3, 2021 /PRNewswire/ -- Researchers from the School of Chinese Medicine (SCM) at Hong Kong Baptist University (HKBU) have developed a Chinese medicine formula named NeuroDefend that offers a potentialnovel treatment for Alzheimer's disease (AD).

Key Points: 
  • HONG KONG, Feb. 3, 2021 /PRNewswire/ -- Researchers from the School of Chinese Medicine (SCM) at Hong Kong Baptist University (HKBU) have developed a Chinese medicine formula named NeuroDefend that offers a potentialnovel treatment for Alzheimer's disease (AD).
  • NeuroDefend was developed by a research team led by Professor Li Min, Professor of the Teaching and Research Division and Associate Dean of the School of Chinese Medicine at HKBU.
  • Three of them were found to be effective in treating Alzheimer's disease in a cell disease model.
  • "Traditional Chinese medicine adopts a broad pharmacological approach to treating neurodegenerative diseases by deploying a combination of herbal medicines with different treatment effects.

HKBU Drug the First in Hong Kong to be Granted Orphan Drug Designation by the US FDA

Retrieved on: 
Wednesday, October 23, 2019
Articles, Health, Life sciences, Pharmaceuticals policy, Biotechnology, Drug discovery, Orphan drug, Food and Drug Administration, Hong Kong Baptist University School of Chinese Medicine, Aptamer

HONG KONG, Oct. 23, 2019 /PRNewswire/ -- A research team from the School of Chinese Medicine at Hong Kong Baptist University(HKBU)has successfully developed anovel aptamer, i.e.

Key Points: 
  • HONG KONG, Oct. 23, 2019 /PRNewswire/ -- A research team from the School of Chinese Medicine at Hong Kong Baptist University(HKBU)has successfully developed anovel aptamer, i.e.
  • It is the first time a drug in Hong Kong has beengranted orphan drug designation by the US Food and Drug Administration (FDA).
  • The designation will bring a series of benefits to the subsequent research and development of the drug, such astax credits when conducting qualifiedclinical trials.
  • OI, which is also known as brittle bone disease, is a rare hereditary bone disease with no effective drugs for treatment.

HKBU Drug the First in Hong Kong to be Granted Orphan Drug Designation by the US FDA

Retrieved on: 
Wednesday, October 23, 2019
Articles, Health, Life sciences, Pharmaceuticals policy, Biotechnology, Drug discovery, Orphan drug, Food and Drug Administration, Hong Kong Baptist University School of Chinese Medicine, Aptamer

HONG KONG, Oct. 23, 2019 /PRNewswire/ -- A research team from the School of Chinese Medicine at Hong Kong Baptist University(HKBU)has successfully developed anovel aptamer, i.e.

Key Points: 
  • HONG KONG, Oct. 23, 2019 /PRNewswire/ -- A research team from the School of Chinese Medicine at Hong Kong Baptist University(HKBU)has successfully developed anovel aptamer, i.e.
  • It is the first time a drug in Hong Kong has beengranted orphan drug designation by the US Food and Drug Administration (FDA).
  • The designation will bring a series of benefits to the subsequent research and development of the drug, such astax credits when conducting qualifiedclinical trials.
  • OI, which is also known as brittle bone disease, is a rare hereditary bone disease with no effective drugs for treatment.